<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506779</url>
  </required_header>
  <id_info>
    <org_study_id>GYN03-0177</org_study_id>
    <secondary_id>NCI-2012-01549</secondary_id>
    <nct_id>NCT00506779</nct_id>
  </id_info>
  <brief_title>Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma</brief_title>
  <official_title>A Phase I/II Study of Gleevec/Taxol in Patients With Newly Diagnosed Stage IIIC or IV or Recurrent (Any Stage) Uterine Papillary Serous Carcinoma (UPSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:&#xD;
&#xD;
        -  To determine the maximum tolerated dose (MTD) of imatinib mesylate in combination with&#xD;
           fixed dose paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary&#xD;
           serous carcinoma.&#xD;
&#xD;
        -  To determine the nature and degree of toxicity of imatinib mesylate and paclitaxel in&#xD;
           this cohort of patients.&#xD;
&#xD;
        -  To determine the efficacy of imatinib mesylate and paclitaxel in patients with stage&#xD;
           IIIC, IV or recurrent uterine papillary serous carcinoma whose tumor expresses either&#xD;
           c-Kit, PDGFR or abl.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before possible study participants can receive treatment with imatinib mesylate and&#xD;
      paclitaxel, their tumor tissue that was previously collected (at the surgery to diagnose your&#xD;
      tumor) will be tested for the following three biomarkers: c-Kit, PDGFR-B, and Abl. Those&#xD;
      participants who have at least one positive biomarker will be eligible for treatment on this&#xD;
      study.&#xD;
&#xD;
      Paclitaxel is a chemotherapy drug used in the treatment of ovarian cancer. Imatinib mesylate&#xD;
      is a medication that blocks several proteins that are important in the development of cancer.&#xD;
&#xD;
      Before treatment starts, you will have a complete physical exam, routine blood tests (about&#xD;
      2-3 teaspoons), an electrocardiogram (ECG--a test to measure the electrical activity of the&#xD;
      heart). You will have an echocardiogram (an ultrasound test used to visualize the structures&#xD;
      of the heart), a chest x-ray, and a CT scan or MRI of the abdomen and pelvis. Women who are&#xD;
      able to have children must have a negative blood pregnancy test.&#xD;
&#xD;
      Routine blood tests (about 2 teaspoons) will be done weekly during treatment, and before each&#xD;
      course of therapy, which is every 3 weeks. A complete checkup including evaluation of side&#xD;
      effects, will also be done before each course of therapy and at the end of therapy (3 weeks&#xD;
      after treatment ends).&#xD;
&#xD;
      There are two phases to this study, Phase I and Phase II. If you are assigned to Phase 1, you&#xD;
      will receive treatment with imatinib mesylate and paclitaxel. Phase 1 will study 3 different&#xD;
      doses of imatinib mesylate in combination with a fixed dose of paclitaxel. The Phase I part&#xD;
      of the study will help researchers learn the most effective dose of imatinib mesylate to be&#xD;
      used in combination with paclitaxel. All participants in Phase 1 will receive one of three&#xD;
      doses of imatinib mesylate to be given with a standard dose of paclitaxel. You will be&#xD;
      assigned to a specific dose level based on the number of participants treated at the time of&#xD;
      your enrollment.&#xD;
&#xD;
      The Phase II portion of the study will begin only after the most effective dose of imatinib&#xD;
      mesylate has been determined.&#xD;
&#xD;
      If you are assigned to Phase II, you will be randomly assigned (as in the toss of a coin) to&#xD;
      one of two treatment groups. Participants in one group will receive treatment with paclitaxel&#xD;
      only (every 21 days). Participants in the second group will receive treatment with paclitaxel&#xD;
      (every 21 days) along with imatinib mesylate (every day). The dose level of imatinib mesylate&#xD;
      that you receive will be the same as the dose used during Phase I. The computer-generated&#xD;
      assignment will favor the treatment group which is more effective. For example, if the&#xD;
      combination of paclitaxel and imatinib mesylate is more effective than paclitaxel alone, then&#xD;
      more patients will be selected to receive the combination therapy.&#xD;
&#xD;
      You will receive paclitaxel by vein over 3 hours every 21 days. Those participants who are&#xD;
      assigned treatment with both paclitaxel and imatinib mesylate will begin taking imatinib&#xD;
      mesylate the day after the first dose of paclitaxel. A single dose of imatinib mesylate will&#xD;
      be taken by mouth every day.&#xD;
&#xD;
      Evaluation of tumor response (for participants who already have the disease) will be&#xD;
      determined by CT scan or MRI and chest x-ray (patients with chest disease). These scans will&#xD;
      be taken after Courses 2 and 4 , then after every 3 courses until the therapy is finished,&#xD;
      and once more at the end of therapy. Patients who show no signs of the disease will be given&#xD;
      a total of up to 6 courses. Patients who have the disease may continue treatment until the&#xD;
      disease gets worse. You will be taken off study if the disease gets worse or intolerable side&#xD;
      effects occur. If you are removed from the study, you will be asked to have a follow-up CT&#xD;
      scan or MRI and chest x-ray to evaluate the tumor.&#xD;
&#xD;
      THIS IS AN INVESTIGATIONAL STUDY. Paclitaxel is commercially available and approved for use&#xD;
      in the treatment of ovarian cancer. GleevecÂ® is also commercially available and approved for&#xD;
      use in the treatment of certain types of adult leukemias and stomach cancers. The combination&#xD;
      of paclitaxel and imatinib mesylate is still investigational and has been approved for use in&#xD;
      research only.&#xD;
&#xD;
      At least 51 and as many as 65 participants will take part in this study. All participants&#xD;
      will be enrolled and treated at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the study was terminated early due to poor enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">December 29, 2003</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Evaluated at 3 weeks (one cycle)</time_frame>
    <description>Maximum Tolerated Dose (MTD) of Oral Imatinib Mesylate in Combination with Fixed Dose Paclitaxel where MTD of Imatinib Mesylate (mg/m^2 daily) to be determined with conventional 3+3 design, MTD is highest dose level in which 6 participants treated with at most 2 experiencing dose limiting toxicity (DLT). Study utilizes Common Terminology for Adverse Events Criteria (CTCAE) version 3.0 for adverse event reporting.&#xD;
Following cohorts of 3 at lower dose levels until 1 of 3 patients experiences DLT; if 1 of 3 patients experiences DLT at dose level, enter 3 additional patients at dose level, if only 1 of 6 patients experiences DLT at dose level, proceed to next higher dose level with cohort of 3; If 2 of 3 or 3 of 6 patients experience DLT, MTD has exceeded. Once DLT exceeded, treat another 3 patients at previous dose if there were only 3 patients treated at that dose level. MTD is highest dose level in which treated 6 patients with at most 2 experiencing the DLT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Response</measure>
    <time_frame>6 weeks to 18 weeks; Best response achieved since study entry where measurable disease defined as =&gt; 1 lesion accurately measured in at least 1 dimension (longest dimension to be recorded)</time_frame>
    <description>Complete Response (CR): Disappearance lesions, no evidence new lesions documented by 2 disease assessments&gt; 4 weeks apart. Partial Response (PR):&gt;30% decrease in sum longest dimensions (LD) all target measurable lesions reference baseline sum of LD; No progression non-target lesions &amp; no new lesions; Documentation by 2 disease assessments &gt;4 weeks apart; Progressive Disease (PD) (ANY of following): &gt;20% increase in sum LD of target lesions reference smallest sum LD or appearance of new lesions within 8 weeks of study entry; Unequivocal progression on existing non-target lesions, other than pleural effusions without cytological proof of neoplastic origin, within 8 weeks of study entry also considered increasing disease. Death due to disease without prior objective documentation of progression; Global deterioration in health attributable to disease requiring change in therapy without objective evidence of progression. Stable disease: Any condition not meeting above criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression</measure>
    <time_frame>Evaluation at at 6 weeks, tumor restaging continued up to 6 cycles (18 weeks) or until disease progression, whichever comes first</time_frame>
    <description>Efficacy of Gleevec and Taxol in Participants defined by tumor progression for participants with measurable disease or recurrent non-measurable disease. Time to tumor progression defined as the time from date of initial treatment to first objective documentation of disease progression. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). After two cycles (6 weeks), participants will undergo clinical and radiographic (participants with measurable disease) tumor restaging or confirmation recurrent non-measurable disease. Evaluation of tumor response (for participants who already have the disease) determined by CT scan or MRI and chest x-ray (participants with chest disease).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Uterine Cancer</condition>
  <arm_group>
    <arm_group_label>Phase I: Paclitaxel + Imatinib Mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I MTD using oral dose Imatinib Mesylate escalation 400, 500, 600 mg daily; Paclitaxel 175 mg/m^2 every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Paclitaxel Alone or Pacliataxel + Imatinib Mesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intended randomization of Paclitaxel alone or Paclitaxel + Imatinib Mesylate; the study was terminated early due to poor enrollment and all patients are no longer being treated or followed. Single treatment arm MTD using oral dose Imatinib Mesylate escalation = 500 mg daily; Paclitaxel 175 mg/m^2 every 21 days&#xD;
Phase II, (Arm 1) = Paclitaxel 175 mg/m^2 every 21 days Phase II, (Arm 2) Paclitaxel 175 mg/m^2 every 21 days+ Imatinib Mesylate MTD using oral dose Imatinib Mesylate escalation = 500 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
    <description>Phase I = Maximum tolerated dose (MTD) derived from dose escalation of 400, 500, 600 mg by mouth daily</description>
    <arm_group_label>Phase I: Paclitaxel + Imatinib Mesylate</arm_group_label>
    <arm_group_label>Phase II: Paclitaxel Alone or Pacliataxel + Imatinib Mesylate</arm_group_label>
    <other_name>Gleevec</other_name>
    <other_name>STI571</other_name>
    <other_name>Imatinib</other_name>
    <other_name>NSC-716051</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m^2 by vein over 3 Hours every 21 Days</description>
    <arm_group_label>Phase I: Paclitaxel + Imatinib Mesylate</arm_group_label>
    <arm_group_label>Phase II: Paclitaxel Alone or Pacliataxel + Imatinib Mesylate</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed newly diagnosed (stage IIIC or IV) or recurrent (any stage)&#xD;
             uterine papillary serous carcinoma. Patients with recurrent disease may not have been&#xD;
             treated with taxanes in the past.&#xD;
&#xD;
          2. Patients may not receive concurrent radiotherapy while participating in this protocol.&#xD;
&#xD;
          3. Patients may have measurable or non-measurable disease.&#xD;
&#xD;
          4. Patients may have mixed endometrioid or clear cell components in addition to the&#xD;
             serous histology.&#xD;
&#xD;
          5. Patients' tumor tissue must express one or more of the following biomarkers: c-Kit,&#xD;
             PDGFR-B, or Abl. Positivity will be defined as 2+/3+ intensity in at least 10% of the&#xD;
             tumor.&#xD;
&#xD;
          6. Patients must have pretreatment granulocyte count (i.e. segmented neutrophils and&#xD;
             bands) of &gt;/= 1,500/Fl, a hemoglobin level of &gt;/= 9.0 gm/dl, and a platelet count of&#xD;
             &gt;/= 100,000/Fl.&#xD;
&#xD;
          7. Patients must have an adequate renal function as documented by serum creatinine of&#xD;
             &lt;/=2.0 mg/dl.&#xD;
&#xD;
          8. Patients must have adequate hepatic function as documented by a serum bilirubin&#xD;
             &lt;/=1.5mg/dl, regardless of whether patients have liver involvement secondary to tumor.&#xD;
             Alanine aminotransferase (SGPT) and aspartate aminotransferase (SGOT) must be &lt;/=2.5x&#xD;
             institutional upper limit of normal unless the liver is involved with tumor, in which&#xD;
             case levels must be &lt;/=5x institutional upper limit of normal.&#xD;
&#xD;
          9. Zubrod performance status of 0, 1, or 2.&#xD;
&#xD;
         10. Patients should not have received prior chemotherapy or radiation (except palliative&#xD;
             radiation) within the last 30 days.&#xD;
&#xD;
         11. Patients must have signed informed consent indicating that they are aware of the&#xD;
             investigational nature of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have previously received imatinib mesylate or taxanes.&#xD;
&#xD;
          2. Patients with any active or uncontrolled systemic infection, including known HIV&#xD;
             infection.&#xD;
&#xD;
          3. Patients with psychiatric disorders that would interfere with consent or follow-up.&#xD;
&#xD;
          4. Patients with New York Heart Association (NYHA) Class III/IV congestive heart failure,&#xD;
             unstable angina or a history of myocardial infarction within the previous 6 months.&#xD;
&#xD;
          5. Patients with a history of prior malignancy except for adequately treated basal cell&#xD;
             or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the&#xD;
             patient has been disease-free for at least three years.&#xD;
&#xD;
          6. Oxygen-dependent lung disease.&#xD;
&#xD;
          7. Patients in whom corticosteroids are contraindicated.&#xD;
&#xD;
          8. Uncontrolled severe hypertension or uncontrolled diabetes mellitus.&#xD;
&#xD;
          9. Presence of clinically apparent central nervous system metastases or carcinomatous&#xD;
             meningitis.&#xD;
&#xD;
         10. Patients with any form of chronic liver disease.&#xD;
&#xD;
         11. Patients with a history of seizures are ineligible. Patients receiving phenytoin,&#xD;
             phenobarbital, or other anti-epileptic prophylaxis are ineligible.&#xD;
&#xD;
         12. Patients with any other severe concurrent disease, which in the judgment of the&#xD;
             investigator, would make the patient inappropriate for entry into this study,&#xD;
             including significant hepatic, renal, or gastrointestinal diseases.&#xD;
&#xD;
         13. Patients with a deep venous or arterial thrombosis (including pulmonary embolism)&#xD;
             within 6 weeks of study entry.&#xD;
&#xD;
         14. Patients who are receiving therapeutic doses of warfarin or any blood thinning agent.&#xD;
&#xD;
         15. Patients with a history of non-compliance with medical regimens or who are considered&#xD;
             potentially unreliable.&#xD;
&#xD;
         16. Pregnant or lactating women. Women of reproductive potential may not participate&#xD;
             unless they have agreed to use an effective contraceptive method.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 23, 2007</study_first_submitted>
  <study_first_submitted_qc>July 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>April 13, 2016</results_first_submitted>
  <results_first_submitted_qc>October 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2020</results_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Papillary Serous Carcinoma</keyword>
  <keyword>Uterine Cancer</keyword>
  <keyword>UPSC</keyword>
  <keyword>Taxol</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Gleevec</keyword>
  <keyword>Imatinib Mesylate</keyword>
  <keyword>STI571</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: December 29, 2003 to October 27, 2009. Recruitment was done at The University of Texas MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>The study was terminated early due to poor enrollment .</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I: Imatinib Mesylate 400 mg</title>
          <description>Cohort One = Paclitaxel (Taxol) 175 mg/m^2 intravenous (IV) every 21 days + Imatinib Mesylate (Gleevec). Phase I Maximum Tolerated Dose (MTD) to be determined from escalating doses in subsequent cohorts: 400 (this arm, Cohort One), 500 (Cohort Two) or 600 mg (Cohort Three) orally daily.</description>
        </group>
        <group group_id="P2">
          <title>Phase I: Imatinib Mesylate 500 mg</title>
          <description>Cohort Two = Paclitaxel 175 mg/m^2 IV every 21 days + Imatinib Mesylate 500 mg orally daily</description>
        </group>
        <group group_id="P3">
          <title>Phase I: Imatinib Mesylate 600 mg</title>
          <description>Cohort Three = Paclitaxel 175 mg/m^2 IV every 21 days + Imatinib Mesylate 600 mg orally daily</description>
        </group>
        <group group_id="P4">
          <title>Phase II: Imatinib Mesylate MTD 500 mg</title>
          <description>Phase II, Cohort 4 = Paclitaxel 175 mg/m^2 IV every 21 days + Imatinib Mesylate at MTD 500 mg orally daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I: Paclitaxel + Imatinib Mesylate</title>
          <description>Phase I = Paclitaxel (Taxol) 175 mg/m^2 intravenous (IV) every 21 days + Imatinib Mesylate (Gleevec) 400, 500 or 600 mg orally daily</description>
        </group>
        <group group_id="B2">
          <title>Phase II: Paclitaxel + Imatinib Mesylate MTD 500 mg</title>
          <description>Phase II = Paclitaxel 175 mg/m^2 IV every 21 days + Imatinib Mesylate at MTD 500 mg orally daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="48" upper_limit="80"/>
                    <measurement group_id="B2" value="70" lower_limit="60" upper_limit="77"/>
                    <measurement group_id="B3" value="64" lower_limit="48" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)</title>
        <description>Maximum Tolerated Dose (MTD) of Oral Imatinib Mesylate in Combination with Fixed Dose Paclitaxel where MTD of Imatinib Mesylate (mg/m^2 daily) to be determined with conventional 3+3 design, MTD is highest dose level in which 6 participants treated with at most 2 experiencing dose limiting toxicity (DLT). Study utilizes Common Terminology for Adverse Events Criteria (CTCAE) version 3.0 for adverse event reporting.&#xD;
Following cohorts of 3 at lower dose levels until 1 of 3 patients experiences DLT; if 1 of 3 patients experiences DLT at dose level, enter 3 additional patients at dose level, if only 1 of 6 patients experiences DLT at dose level, proceed to next higher dose level with cohort of 3; If 2 of 3 or 3 of 6 patients experience DLT, MTD has exceeded. Once DLT exceeded, treat another 3 patients at previous dose if there were only 3 patients treated at that dose level. MTD is highest dose level in which treated 6 patients with at most 2 experiencing the DLT.</description>
        <time_frame>Evaluated at 3 weeks (one cycle)</time_frame>
        <population>One participant of 12 registered withdrew prior to receiving treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib Mesylate 400 mg</title>
            <description>Cohort One = Paclitaxel 175 mg/m^2 IV every 21 days + Imatinib Mesylate 400 mg orally daily</description>
          </group>
          <group group_id="O2">
            <title>Imatinib Mesylate 500 mg</title>
            <description>Cohort Two = Paclitaxel 175 mg/m^2 IV every 21 days + Imatinib Mesylate 500 mg orally daily</description>
          </group>
          <group group_id="O3">
            <title>Imatinib Mesylate 600 mg</title>
            <description>Cohort Three = Paclitaxel 175 mg/m^2 IV every 21 days + Imatinib Mesylate 600 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Dose Limiting Toxicities (DLTs)</title>
          <description>Maximum Tolerated Dose (MTD) of Oral Imatinib Mesylate in Combination with Fixed Dose Paclitaxel where MTD of Imatinib Mesylate (mg/m^2 daily) to be determined with conventional 3+3 design, MTD is highest dose level in which 6 participants treated with at most 2 experiencing dose limiting toxicity (DLT). Study utilizes Common Terminology for Adverse Events Criteria (CTCAE) version 3.0 for adverse event reporting.&#xD;
Following cohorts of 3 at lower dose levels until 1 of 3 patients experiences DLT; if 1 of 3 patients experiences DLT at dose level, enter 3 additional patients at dose level, if only 1 of 6 patients experiences DLT at dose level, proceed to next higher dose level with cohort of 3; If 2 of 3 or 3 of 6 patients experience DLT, MTD has exceeded. Once DLT exceeded, treat another 3 patients at previous dose if there were only 3 patients treated at that dose level. MTD is highest dose level in which treated 6 patients with at most 2 experiencing the DLT.</description>
          <population>One participant of 12 registered withdrew prior to receiving treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Response</title>
        <description>Complete Response (CR): Disappearance lesions, no evidence new lesions documented by 2 disease assessments&gt; 4 weeks apart. Partial Response (PR):&gt;30% decrease in sum longest dimensions (LD) all target measurable lesions reference baseline sum of LD; No progression non-target lesions &amp; no new lesions; Documentation by 2 disease assessments &gt;4 weeks apart; Progressive Disease (PD) (ANY of following): &gt;20% increase in sum LD of target lesions reference smallest sum LD or appearance of new lesions within 8 weeks of study entry; Unequivocal progression on existing non-target lesions, other than pleural effusions without cytological proof of neoplastic origin, within 8 weeks of study entry also considered increasing disease. Death due to disease without prior objective documentation of progression; Global deterioration in health attributable to disease requiring change in therapy without objective evidence of progression. Stable disease: Any condition not meeting above criteria.</description>
        <time_frame>6 weeks to 18 weeks; Best response achieved since study entry where measurable disease defined as =&gt; 1 lesion accurately measured in at least 1 dimension (longest dimension to be recorded)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With Measurable Disease</title>
            <description>Paclitaxel (Taxol) 175 mg/m^2 intravenous (IV) every 21 days + Imatinib Mesylate (Gleevec) 400, 500 or 600 mg orally daily or Phase II MTD 500 mg</description>
          </group>
          <group group_id="O2">
            <title>Participants With Non-Measurable Disease</title>
            <description>Paclitaxel (Taxol) 175 mg/m^2 intravenous (IV) every 21 days + Imatinib Mesylate (Gleevec) 400, 500 or 600 mg orally daily or Phase II MTD 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Response</title>
          <description>Complete Response (CR): Disappearance lesions, no evidence new lesions documented by 2 disease assessments&gt; 4 weeks apart. Partial Response (PR):&gt;30% decrease in sum longest dimensions (LD) all target measurable lesions reference baseline sum of LD; No progression non-target lesions &amp; no new lesions; Documentation by 2 disease assessments &gt;4 weeks apart; Progressive Disease (PD) (ANY of following): &gt;20% increase in sum LD of target lesions reference smallest sum LD or appearance of new lesions within 8 weeks of study entry; Unequivocal progression on existing non-target lesions, other than pleural effusions without cytological proof of neoplastic origin, within 8 weeks of study entry also considered increasing disease. Death due to disease without prior objective documentation of progression; Global deterioration in health attributable to disease requiring change in therapy without objective evidence of progression. Stable disease: Any condition not meeting above criteria.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tumor Progression</title>
        <description>Efficacy of Gleevec and Taxol in Participants defined by tumor progression for participants with measurable disease or recurrent non-measurable disease. Time to tumor progression defined as the time from date of initial treatment to first objective documentation of disease progression. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). After two cycles (6 weeks), participants will undergo clinical and radiographic (participants with measurable disease) tumor restaging or confirmation recurrent non-measurable disease. Evaluation of tumor response (for participants who already have the disease) determined by CT scan or MRI and chest x-ray (participants with chest disease).</description>
        <time_frame>Evaluation at at 6 weeks, tumor restaging continued up to 6 cycles (18 weeks) or until disease progression, whichever comes first</time_frame>
        <population>Due to poor enrollment, the study was terminated early and no data collected for the Time to tumor progression outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Measurable Disease</title>
            <description>Paclitaxel (Taxol) 175 mg/m^2 intravenous (IV) every 21 days + Imatinib Mesylate (Gleevec) 400, 500 or 600 mg orally daily or Phase II MTD 500 mg</description>
          </group>
          <group group_id="O2">
            <title>Participants With Non-Measurable Disease</title>
            <description>Paclitaxel (Taxol) 175 mg/m^2 intravenous (IV) every 21 days + Imatinib Mesylate (Gleevec) 400, 500 or 600 mg orally daily or Phase II MTD 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tumor Progression</title>
          <description>Efficacy of Gleevec and Taxol in Participants defined by tumor progression for participants with measurable disease or recurrent non-measurable disease. Time to tumor progression defined as the time from date of initial treatment to first objective documentation of disease progression. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). After two cycles (6 weeks), participants will undergo clinical and radiographic (participants with measurable disease) tumor restaging or confirmation recurrent non-measurable disease. Evaluation of tumor response (for participants who already have the disease) determined by CT scan or MRI and chest x-ray (participants with chest disease).</description>
          <population>Due to poor enrollment, the study was terminated early and no data collected for the Time to tumor progression outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event collection with each 3 week cycle, up to 6 cycles (18 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I: Imatinib Mesylate 400mg</title>
          <description>Cohort One = Paclitaxel (Taxol) 175 mg/m^2 intravenous (IV) every 21 days + Imatinib Mesylate (Gleevec). Phase I Maximum Tolerated Dose (MTD) to be determined from escalating doses in subsequent cohorts: 400 (this arm, Cohort One), 500 (Cohort Two) or 600 mg (Cohort Three) orally daily.</description>
        </group>
        <group group_id="E2">
          <title>Phase II: Imatinib Mesylate 500 mg</title>
          <description>Paclitaxel 175 mg/m^2 IV every 21 days + Imatinib Mesylate 500 mg orally daily</description>
        </group>
        <group group_id="E3">
          <title>Phase 1: Imatinib Mesylate 600 mg</title>
          <description>Paclitaxel 175 mg/m^2 IV every 21 days + Imatinib Mesylate 600 mg orally daily</description>
        </group>
        <group group_id="E4">
          <title>Phase II: Imatinib Mesylate MTD 500 mg</title>
          <description>Paclitaxel 175 mg/m^2 IV every 21 days + Imatinib Mesylate at MTD 500 mg orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever w/o Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain - abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain - pleura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>SGOT - elevated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>SGPT - elevated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain - Joint</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain - Muscle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pain - bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rash - desquamation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Edema - facial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Gershenson, MD</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-745-2565</phone>
      <email>DGershen@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

